Exelixis
EXEL
#1725
Rank
$9.50 B
Marketcap
$33.29
Share price
-1.16%
Change (1 day)
41.78%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2024 : $2.96 Billion USD

According to Exelixis's latest financial reports the company's total assets are $2.96 Billion USD. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31$2.94 B-4.2%
2022-12-31$3.07 B17.4%
2021-12-31$2.61 B22.41%
2020-12-31$2.13 B13.35%
2019-12-31$1.88 B32.58%
2018-12-31$1.42 B117.05%
2017-12-31$0.65 B10%
2016-12-31$0.59 B79.25%
2015-12-31$0.33 B2.81%
2014-12-31$0.32 B-35.77%
2013-12-31$0.50 B-30.21%
2012-12-31$0.72 B83.36%
2011-12-31$0.39 B9%
2010-12-31$0.36 B5.06%
2009-12-31$0.34 B-14.49%
2008-12-31$0.40 B-2.55%
2007-12-31$0.41 B4.22%
2006-12-31$0.39 B18.85%
2005-12-31$0.33 B14.2%
2004-12-31$0.29 B-18.57%
2003-12-31$0.35 B5.51%
2002-12-31$0.33 B-2.16%
2001-12-31$0.34 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
$77.68 B 2,524.37%๐Ÿ‡ฌ๐Ÿ‡ง UK
$139.09 B 4,598.71%๐Ÿ‡ซ๐Ÿ‡ท France
$117.53 B 3,870.30%๐Ÿ‡บ๐Ÿ‡ธ USA
$93.67 B 3,064.23%๐Ÿ‡บ๐Ÿ‡ธ USA
$90.88 B 2,970.08%๐Ÿ‡บ๐Ÿ‡ธ USA
$178.28 B 5,922.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$219.47 B 7,314.03%๐Ÿ‡บ๐Ÿ‡ธ USA
$42.47 M-98.57%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.10 B-96.58%๐Ÿ‡บ๐Ÿ‡ธ USA